Quang X. Pham

Form D signer

Quang X. Pham

Chief Executive Officer at Cadrenal Therapeutics

Form D signer

Capital raised by Cadrenal Therapeutics

$16.8M+$8.8M latest round

2 Form D filings · first filed Apr 2026 · Ponte Vedra, FL

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 2
TEAM ON FILE: 3
FOUNDED: 2022
30D INTEREST: 1 ↗

Career

1 company on file · founded 2022

Cadrenal TherapeuticsBiotech · Ponte Vedra, FLsince 2022

Chief Executive Officer

Signatory on Cadrenal Therapeutics's Form D filings · $16.8M raised across 2

Company filings

via EDGAR · Form D for Cadrenal Therapeutics2

DateCompanyFormAmountRole on filing

Jun 30, 2026Cadrenal TherapeuticsForm D+$8.8MChief Executive Officer

Form DJun 30, 2026 · Cadrenal Therapeutics+$8.8Mas Chief Executive Officer

Apr 1, 2026Cadrenal TherapeuticsForm D+$7.9MChief Executive Officer

Form DApr 1, 2026 · Cadrenal Therapeutics+$7.9Mas Chief Executive Officer

Overview

Last filing Jun 30, 2026

Quang X. Pham is on file as Chief Executive Officer at Cadrenal Therapeutics in Ponte Vedra, FL. Cadrenal Therapeutics has 2 Form D filings on record, $16.8M raised in total. Quang X. Pham appears as a signatory on the company's filings.

LinkedIn profile

Teammates

Cadrenal Therapeutics · 2

Glynn WilsonDirector Lee GoldenDirector

Products

Cadrenal Therapeutics · 1

CAD-1005Clinical-stage therapeutic

A first-in-class 12-lipoxygenase (12-LOX) inhibitor for heparin-induced thrombocytopenia (HIT), an immune-mediated thrombotic disorder. It is Phase 3-ready and holds FDA Orphan Drug and Fast Track designations.